Expanded Access to Velmanase Alfa

NCT ID: NCT04959240

Last Updated: 2023-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Individual patient expanded access requests may be considered for patients who have no other treatment options.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Expanded access may provide access for treatment prior to approval by the local regulatory agency.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alpha-Mannosidosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Velmanase Alfa

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lamzede Lamazym rhLAMAN recombinant human alpha-mannosidase

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Eligible Sex

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chiesi Farmaceutici S.p.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Expanded Access

Role: CONTACT

(888) 661-9260

Clinical Trials

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Velmanase alfa-EAP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Monthly Dosing of Atacicept in IgAN
NCT07020923 RECRUITING PHASE2